Emmaus Life Sciences Changes Auditors

TL;DR

Emmaus Life Sciences swapped auditors, moving from Sadler, Gibb & Associates to Weaver and Associates.

AI Summary

Emmaus Life Sciences, Inc. filed an 8-K on September 5, 2024, reporting changes in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, Sadler, Gibb & Associates, LLC, and has appointed Weaver and Associates, CPAs, LLP as its new auditor. This change is effective immediately.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial scrutiny or restatements, warranting a medium risk assessment.

Key Players & Entities

• Emmaus Life Sciences, Inc. (company) — Registrant
• Sadler, Gibb & Associates, LLC (company) — Former Certifying Accountant
• Weaver and Associates, CPAs, LLP (company) — New Certifying Accountant
• September 5, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• ea021395101-8k_emmaus.htm (8-K) — 30KB
• ea021395101ex16-1_emmaus.htm (EX-16.1) — 4KB
• ea021395101ex99-1_emmaus.htm (EX-99.1) — 40KB
• image_001.jpg (GRAPHIC) — 8KB
• ex16-1_001.jpg (GRAPHIC) — 23KB
• ex16-1_002.jpg (GRAPHIC) — 26KB
• 0001213900-24-077411.txt ( ) — 329KB
• emma-20240905.xsd (EX-101.SCH) — 3KB
• emma-20240905_lab.xml (EX-101.LAB) — 33KB
• emma-20240905_pre.xml (EX-101.PRE) — 22KB
• ea021395101-8k_emmaus_htm.xml (XML) — 3KB

02 Results of Operation and Financial Condition

Item 2.02 Results of Operation and Financial Condition. On September 10, 2024, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing the results of operations and financial condition as of and for the six months ended June 30, 2024, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Changes in Registrant's Certifying

Item 4.01 Changes in Registrant's Certifying Accountant On September 5, 2024, Baker Tilly US, LLP, or BT, notified the Audit Committee of our Board of Directors that they would not stand for reappointment as our independent registered public accountants for the year ending December 31, 2024. Accordingly, we will undertake to evaluate and retain a replacement independent registered public accounting firm in time to review our interim financial statements for the quarter ending September 30, 2024. The audit reports of BT on our consolidated financial statements for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except that such report contained an explanatory paragraph regarding the Company's ability to continue as a going concern. During the years ended December 31, 2023 and 2022 and subsequent interim periods through the date of this Current Report, there have been no disagreements with BT on any matter of accounting principles or practices, financial statement disclosure, or audit scope or procedure, which disagreements, if not resolved to the satisfaction of BT, would have caused BT to refer to the subject matter of the disagreement in connection with its reports on our financial statements for such periods. During the two most recent years ended December 31, 2023 and 2022, there were no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K. We have provided BT with a copy of this Current Report and requested that BT furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein and, if not, stating the respects with which it does not agree. A copy of BT's letter dated September 10, 2024 is filed as Exhibit 16.1 to this Current Report.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 16.1 September 10, 2024 Letter of Baker Tilly US, LLP to the Securities and Exchange Commission 99.1 September 10, 2024 Press Release 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR